Johns Hopkins Medicine: Pancreatic Cancer Vaccine Plus Immunotherapy and Antibody Spark Immune System Response in Pancreatic Cancers
July 18, 2023
July 18, 2023
BALTIMORE, Maryland, July 18 (TNSjou) -- Johns Hopkins Medicine issued the following news release:
Giving patients with operable pancreatic cancers a three-pronged combination immunotherapy treatment consisting of the pancreatic cancer vaccine GVAX, the immune checkpoint therapy nivolumab and urelemab, an anti-CD137 agonist antibody treatment, is safe, it increases the amount of cancer-killing immune system T cells in the tumors and it appears effective when given two weeks prior to . . .
Giving patients with operable pancreatic cancers a three-pronged combination immunotherapy treatment consisting of the pancreatic cancer vaccine GVAX, the immune checkpoint therapy nivolumab and urelemab, an anti-CD137 agonist antibody treatment, is safe, it increases the amount of cancer-killing immune system T cells in the tumors and it appears effective when given two weeks prior to . . .